Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Brachytherapy ; 20(3): 624-630, 2021.
Article in English | MEDLINE | ID: mdl-33685816

ABSTRACT

PURPOSE: In France, the reference technique for skin cancer was low-dose-rate brachytherapy (BT) delivered via iridium wire. At the end of their commercialization in 2015 we have replaced them by high-dose-rate (HDR) BT via interstitial catheters. We assessed efficacy and tolerance as soon as this technique was implemented. METHODS AND MATERIALS: Patients received 7 Gy on the first day, followed by 8 × 4 Gy over the next 4 days for exclusive BT and 9 × 4 Gy over 5 days for post-operative BT. RESULTS: Sixty-six patients of median age 81 years received a total of 58 primary BT and 13 post-operative BT for non-melanoma facial skin cancers. Implantation was without difficulty. Median follow up was 15.3 months. Two patients died of intercurrent diseases before first follow up. For the others, 98.5% showed complete response and 3% local recurrence after a median of 20.5 months. Four patients had grade 3 acute dermatitis and three patients had grade 3 mucositis. All the Grade 3 toxicities were resolved within 3 months. A late significant hypopigmentation occurred in 4 patients. CONCLUSIONS: HDR BT is efficient and well-tolerated with good cosmetic results. HDR catheters are similar with iridium wires in terms of technical difficulty.


Subject(s)
Brachytherapy , Prostatic Neoplasms , Skin Neoplasms , Aged, 80 and over , Brachytherapy/methods , France/epidemiology , Humans , Male , Neoplasm Recurrence, Local , Skin Neoplasms/radiotherapy
2.
Brachytherapy ; 13(6): 597-602, 2014.
Article in English | MEDLINE | ID: mdl-24913434

ABSTRACT

PURPOSE: Pulsed-dose-rate (PDR) brachytherapy is thought to mimic the radiobiological benefits of continuous low-dose-rate (cLDR) delivery but is safer for medical personnel. We set out to evaluate the outcomes of this technique in patients with head and neck squamous cell carcinoma. METHODS AND MATERIALS: A total of 36 consecutive patients treated with PDR brachytherapy were randomly matched to 72 cLDR controls according to T-stage, tumor site, and management strategy. Local recurrence and late complications were compared between the two groups. RESULTS: Baseline characteristics were similar in both groups. Oral cavity cancers predominated at 81%, and 89% had T1/T2 tumors. Seventy-five percent of patients underwent surgery before radiation treatment. Median followup was 59 and 30 months for cLDR and PDR patients, respectively. Three-year actuarial local recurrence-free survival was 97% and 94% for cLDR and PDR patients, respectively (p = 0.77). Three-year cumulative risk of Grade ≥2 complications was 45% and 32% for cLDR and PDR patients, respectively (p = 0.2). For cLDR, a dose rate exceeding 68 cGy/h resulted in more complications (RR 5.3, p < 0.05). Similarly, PDR patients receiving ≥75 cGy/pulse were at higher risk. CONCLUSIONS: PDR brachytherapy in head and neck squamous cell carcinoma yields comparable results to cLDR treatment. Dose rate was correlated with the risk of late complications, regardless of technique.


Subject(s)
Brachytherapy/methods , Carcinoma, Squamous Cell/radiotherapy , Dose Fractionation, Radiation , Head and Neck Neoplasms/radiotherapy , Mouth Neoplasms/radiotherapy , Oropharyngeal Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Case-Control Studies , Clinical Protocols , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/prevention & control , Neoplasm Recurrence, Local/radiotherapy , Radiotherapy Dosage , Squamous Cell Carcinoma of Head and Neck
3.
Int J Radiat Oncol Biol Phys ; 58(5): 1353-63, 2004 Apr 01.
Article in English | MEDLINE | ID: mdl-15050310

ABSTRACT

PURPOSE: To report the results of arc-therapy radiosurgery for cerebral arteriovenous malformation (AVM) and to compare the adverse event rate with the rate expected from the natural history. METHODS AND MATERIALS: We performed a retrospective study of our 118 first patients with a mean follow-up of 46 months (range, 5-105 months). The AVMs had features indicating a poor prognosis at initial presentation and had already been treated by previous embolizations in 88% of patients. The mean volume of the targets was 7.4 cm3 (range, 0.3-28.3 cm3). The mean minimal and maximal dose was 17.7 Gy (range, 10-25 Gy) and 24.5 Gy (range, 17-36 Gy), respectively. RESULTS: The crude and 5-year actuarial rate of cure (total obstruction of the AVM shunt at angiography) was 54% (60 of 112) and 77%, respectively. The only independent prognostic factor of cure was the AVM volume (crude cure rate 67% for <7 cm3 vs. 35% for > or =7 cm3; p = 0.001). No patient died. Transient and permanent complications and hemorrhage occurred in 5%, 1.7%, and 6% of patients, respectively. The annual risk of an adverse event (hemorrhage or complication) was 3.9%. CONCLUSION: The results of our series showed that radiosurgery, performed alone or after prior shrinkage of the AVM by embolization, is both effective and well tolerated, with a rate of adverse events comparable to that expected from the natural history.


Subject(s)
Cerebral Hemorrhage/etiology , Intracranial Arteriovenous Malformations/surgery , Radiosurgery/adverse effects , Adolescent , Adult , Aged , Confusion/etiology , Embolization, Therapeutic , Epidemiologic Methods , Female , Humans , Intracranial Arteriovenous Malformations/therapy , Male , Middle Aged , Prognosis , Radiation Injuries/etiology , Radiosurgery/methods , Radiotherapy Dosage , Salvage Therapy
SELECTION OF CITATIONS
SEARCH DETAIL